Investing in Milestone Pharmaceuticals involves significant financial and operational risks common among commercial-stage biopharmaceutical enterprises. The primary risk centers on the commercial adoption and market uptake of its newly launched flagship product, as physician acceptance, insurance reimbursement approvals, and patient demand must scale rapidly to justify operational expenditures. Additionally, the company faces ongoing financial risks associated with high cash burn rates required to fund marketing expansion, medical education, and pipeline development for secondary indications like atrial fibrillation. Regulatory hurdles, potential manufacturing bottlenecks, intellectual property challenges, and the inherent volatility of small-cap healthcare equities can also lead to sharp downward share price revisions if quarterly sales metrics fail to meet high market expectations.